ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Adipose Tissue Involvement in Alcohol-Induced Liver Inflammation in Human : Study of Pro- and Anti-Inflammatory Cytokines and Adipokines.

This study is not yet open for participant recruitment.
Verified by Assistance Publique - Hôpitaux de Paris, October 2006

Sponsored by: Assistance Publique - Hôpitaux de Paris
Information provided by: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT00388323
  Purpose

The histological characteristics of alcoholic liver disease (ALD) and non-alcoholic steatohepatitis (NASH) related to overweight and obesity suggest the presence of partly common physiopathological mechanisms. We reported that the ponderal overload was an independent risk factor of alcoholic cirrhosis. The adipose tissue was considered for a long time as a simple place of storage of fat. However, it is now recognized that the adipose tissue can secrete cytokines called adipokines.

The adipose tissue can secrete others cytokines such as TNF α, lL6, IL10 and IL1-Ra. Increase in the production of the leptin and TNFα by the adipose tissue after alcohol administration in the rat, as well as the role of leptin in inflammation and liver fibrogenesis in the murine model of chemical hepatotoxicity strongly suggest that activation of adipocytes by alcohol can explain the strong correlation observed between the body mass index (BMI) and the severity of ethanol-induced liver injury. Conversely, it was suggested in a murine model that the reduction in adiponectin production would sensitize the liver with the toxicity of alcohol. The PPAR α and γ are the receptors which play a role both in inflammation and glucid and lipid metabolism. Taking into account the inhibiting role of PPAR α on the proliferation of the hepatic stellate cells, responsible for the fibrosis, the PPARs could also be implied in the relation between the overweight and the hepatic fibrosis in the alcoholic.

The aim of this project is to demonstrate that adipokines, as well as the PPAR α et γ are implied in the intensity of the steatosis and in the regulation of the inflammatory process and the hepatic fibrogenesis in alcoholic liver disease. In order to prove this hypothesis, we will study among patients having a ALD at various stages of histological severity: 1) the hepatic and subcutaneous abdominal adipose tissue expression of the PPAR α and PPAR γ 2)the hepatic and subcutaneous abdominal adipose tissue expression of the TNF α, the IL1Ra, the IL6 and the IL10; 3)the hepatic and subcutaneous abdominal adipose tissue expression of the adipokines (leptin, adiponectin, resistin); 4) the serum adipokine values, the cynetic of the mRNA expression and of the serum adipokine values after 7 days of alcohol withdrawal 50 patients will be studied (25 having ALD without cirrhosis, with or without acute alcoholic hepatitis (AAH) and 25 having alcoholic cirrhosis with or without AAH). A part of liver biopsy will be frozen in a dry tube. The percutaneous adipose tissue will be obtained with a ponction on the abdominal level at the time of inclusion of the patients having AAH and, for the second time, after 7 days of alcohol withdrawal, than will be frozen. The TNF α, the IL1Ra, the IL6, the IL10, the leptin, the adiponectin and the resistin expression as well as the hepatic and adipose tissue PPAR α and γ will be evaluated by PCR in real time. The serum concentration of the adipokines (leptin, adiponectin, resistin) will be measured by ELISA or RIA.

If our hypothesis is true, severity of liver lesions (steatosis, AAH, fibrosis) could be positively correlated with the expression in the liver and the adipose tissue and/or the serum values of the anti-inflammatory cytokines and adipokines (TNF α, IL6, leptin, resistin) and negatively with the cytokines and adipokines which are potentially anti-inflammatory (IL1Ra, IL10, adiponectin). We also expect to find a negative correlation between the amount of hepatic and adipose tissue PPAR-α and PPAR-γ mRNA and the severity of the liver disease.


Condition Phase
Alcoholic Hepatitis
Alcoholic Cirrhosis
Phase III

MedlinePlus related topics:   Cirrhosis    Hepatitis    Liver Diseases   

ChemIDplus related topics:   Ethanol    Proline   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Natural History, Cross-Sectional, Defined Population, Prospective Study
Official Title:   Rôle du Tissu Adipeux Dans l’Inflammation hépatique liée à l’Alcool Chez l’Homme : étude Des Adipokines et Des Cytokines Pro- et Anti-Inflammatoires.

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Estimated Enrollment:   50
Study Start Date:   November 2006
Estimated Study Completion Date:   October 2008

  Eligibility
Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Alcoholic patients of both sex aged from 18 to 75, hospitalized for alcoholic liver disease.
  • HBs antigen negative, HIV negative, anti –VHC negative
  • daily consumption exceeded 40-50 grams per day during the last year
  • elevated AST level and liver biopsy during the hospitalisation Patients who signed the informed consent document
  • patients affiliated to the national health insurance system (sécurité sociale)

Exclusion Criteria:

  • patients having another cause than alcohol for liver injury - hepatocellular carcinoma or another developing cancer, severe associated pathology (cardiac disease, respiratory insufficency, severe psychiatric problems), pancreatitis, infection, diabetes or a dyslipidemia
  • patients treated with fibrates or other hypolipidic drugs, oral antidiabetics
  • or insulin
  • patients having hemostasis which does not permit the transcostal liver biopsy, platelet level <60 giga/l, or Quick test < 50 %, or (TCA higher than 1,5 times the time of the witness)
  • patients refuse an adipose tissue biopsy
  • patients treated with long-duration dose of clopidogrel (Plavix®)
  • patients who significantly diminished alcohol consumption in comparison with the average consumption during the year preceding the inclusion
  • patients not-affiliated to the national health insurance system (sécurité sociale)
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00388323

Locations
France
Hôpital Antoine Béclère     Not yet recruiting
      Clamart, France, 92140
      Contact: Gabriel PERLEMUTER, MD     33 1 45 37 43 69     gabriel.perlemuter@abc.aphp.fr    

Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris

Investigators
Principal Investigator:     Gabriel PERLEMUTER, MD     Hôpital Antoine Béclère – Clamart - FRANCE    
  More Information


Study ID Numbers:   P 051041, AOR 05049
First Received:   October 13, 2006
Last Updated:   October 13, 2006
ClinicalTrials.gov Identifier:   NCT00388323
Health Authority:   France: Institutional Ethical Committee

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Alcohol  
Hepatitis  
Cirrhosis  
Inflammation  
Cytokines
Adipokines
Adipose tissue

Study placed in the following topic categories:
Alcohol-Induced Disorders
Liver Diseases
Fibrosis
Disorders of Environmental Origin
Liver Cirrhosis
Inflammation
Hepatitis
Liver Diseases, Alcoholic
Digestive System Diseases
Hepatitis, Alcoholic
Substance-Related Disorders
Alcohol-Related Disorders
Liver Cirrhosis, Alcoholic
Ethanol

Additional relevant MeSH terms:
Pathologic Processes

ClinicalTrials.gov processed this record on September 19, 2008




Links to all studies - primarily for crawlers